This inventor holds 1 USPTO granted patent. Top assignees: California Institute of Technology, Children's Hospital Los Angeles. Active years: 2011.
Company Filing History:
1 out of 4,622 
1 out of 69 
Years Active: 2011
Title: Ben Deneen: Innovator in Glioma Therapy
Introduction
Ben Deneen is an accomplished inventor based in Alhambra, California, renowned for his contributions to the field of medical research. With one patent to his name, his work has focused on critical advancements in glioma therapy and astrocytoma treatment. His innovative approach aims to harness the power of NFIA inhibitors to improve patient outcomes in battling these challenging conditions.
Latest Patents
Deneen's significant patent is titled "NFIA in glial fate determination, glioma therapy and astrocytoma treatment." This invention discloses compositions that incorporate NFIA inhibitors, as well as methods for their application in treating glioma and astrocytomas. This patent represents a promising development in the quest for effective therapies against these aggressive brain tumors.
Career Highlights
Throughout his career, Ben Deneen has worked with prestigious organizations that have advanced his research. Notably, he has been affiliated with the California Institute of Technology and Children's Hospital Los Angeles. These institutions have provided him with a platform to innovate and collaborate on vital research initiatives.
Collaborations
In his journey as an inventor, Deneen has had the opportunity to collaborate with esteemed colleagues, including David J Anderson and Hae-Ri Song. These partnerships have likely enriched his research, allowing for diverse insights and exploration of new pathways in glioma and astrocytoma treatment.
Conclusion
Ben Deneen is a notable figure in the realm of medical innovation, particularly in the fight against gliomas and astrocytomas. His patent on NFIA inhibitors opens new avenues for research and treatment methods, showcasing the potential of scientific innovation to change lives. As ongoing research continues, Deneen's contributions will remain a pivotal part of advancements in neuro-oncology.